YD Bio (NASDAQ:YDES) Trading 7.9% Higher - Still a Buy?

Key Points

• YD Bio surged 7.9% mid-day to $7.8770 (high of $7.50) on extremely light volume—roughly 759 shares, about 98% below its average daily volume of 37,850.
• Analysts carry an average rating of "Sell", though Wall Street Zen recently upgraded the stock to Hold while Weiss Ratings reaffirmed a Sell (d+).
• Institutional interest ticked up as Geode Capital Management increased its position by 10% to 58,363 shares (about $711,000), representing roughly 0.08% ownership per its latest 13F filing.

YD Bio Limited (NASDAQ:YDES - Get Free Report) was up 7.9% during mid-day trading on Monday . The company traded as high as $7.50 and last traded at $7.8770. Approximately 759 shares were traded during trading, a decline of 98% from the average daily volume of 37,850 shares. The stock had previously closed at $7.30.

Analyst Ratings Changes

A number of research firms recently issued reports on YDES. Wall Street Zen upgraded YD Bio from a "sell" rating to a "hold" rating in a research report on Saturday, February 28th. Weiss Ratings reaffirmed a "sell (d+)" rating on shares of YD Bio in a research report on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company has an average rating of "Sell".

YD Bio Stock Up 5.7%

The stock's 50 day moving average is $10.26.

Institutional Trading of YD Bio

An institutional investor recently raised its position in YD Bio stock. Geode Capital Management LLC lifted its stake in shares of YD Bio Limited (NASDAQ:YDES - Free Report) by 10.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 58,363 shares of the biotechnology company's stock after purchasing an additional 5,292 shares during the quarter. Geode Capital Management LLC owned 0.08% of YD Bio worth $711,000 as of its most recent filing with the Securities and Exchange Commission.

About YD Bio

YD Bio Limited is a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.